Philip D Dunne

List of Publications by Year
in descending order

57 papers	5,756 citations	257101 24 h-index	143772 57 g-index
67 all docs	67 docs citations	67 times ranked	11806 citing authors

#	Article	IF	Citations
1	QuPath: Open source software for digital pathology image analysis. Scientific Reports, 2017, 7, 16878.	1.6	3,854
2	Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning. Gut, 2021, 70, 544-554.	6.1	148
3	Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4095-4104.	3.2	135
4	The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. Nature Genetics, 2021, 53, 16-26.	9.4	114
5	EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. Clinical Cancer Research, 2016, 22, 230-242.	3.2	97
6	AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer. Clinical Cancer Research, 2014, 20, 164-175.	3.2	95
7	ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer. Cell Reports, 2014, 7, 1940-1955.	2.9	90
8	Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. Cell Death and Disease, 2014, 5, e1046-e1046.	2.7	77
9	Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification. Nature Communications, 2017, 8, 15657.	5.8	70
10	Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer. Cancer Immunology Research, 2018, 6, 1426-1441.	1.6	66
11	DNMT1 deficiency triggers mismatch repair defects in human cells through depletion of repair protein levels in a process involving the DNA damage response. Human Molecular Genetics, 2011, 20, 3241-3255.	1.4	63
12	Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis. Histopathology, 2018, 73, 327-338.	1.6	63
13	Gremlin1 plays a key role in kidney development and renal fibrosis. American Journal of Physiology - Renal Physiology, 2017, 312, F1141-F1157.	1.3	58
14	Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification. Gut, 2020, 69, 1092-1103.	6.1	52
15	Prospective patient stratification into robust cancerâ€cell intrinsic subtypes from colorectal cancer biopsies. Journal of Pathology, 2018, 245, 19-28.	2.1	49
16	Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage <scp>II</scp>/<scp>III</scp> colon cancer in a large populationâ€based study. Histopathology, 2017, 71, 12-26.	1.6	48
17	Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy. JCO Precision Oncology, 2018, 2018, 1-15.	1.5	45
18	Signalling mechanisms underlying doxorubicin and Nox2 NADPH oxidaseâ€induced cardiomyopathy: involvement of mitofusinâ€2. British Journal of Pharmacology, 2017, 174, 3677-3695.	2.7	38

#	Article	IF	Citations
19	Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. British Journal of Cancer, 2017, 117, 203-209.	2.9	38
20	Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer. Oncotarget, 2016, 7, 78932-78945.	0.8	36
21	Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy. Cancer Immunology Research, 2016, 4, 582-591.	1.6	35
22	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. British Journal of Cancer, 2017, 117, 347-352.	2.9	31
23	The Intricate Interplay between Epigenetic Events, Alternative Splicing and Noncoding RNA Deregulation in Colorectal Cancer. Cells, 2019, 8, 929.	1.8	28
24	cudaMap: a GPU accelerated program for gene expression connectivity mapping. BMC Bioinformatics, 2013, 14, 305.	1.2	25
25	QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics. BMC Bioinformatics, 2016, 17, 198.	1.2	25
26	Epithelialâ€toâ€mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition. Journal of Pathology, 2018, 246, 422-426.	2.1	25
27	Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. Modern Pathology, 2017, 30, 1287-1298.	2.9	23
28	The pseudo-caspase FLIP(L) regulates cell fate following p53 activation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17808-17819.	3.3	18
29	Defining the molecular evolution of extrauterine high grade serous carcinoma. Gynecologic Oncology, 2019, 155, 305-317.	0.6	17
30	Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets identified candidate drugs including existing chemotherapies. BMC Systems Biology, 2015, 9, S4.	3.0	16
31	Standardising RNA profiling based biomarker application in cancerâ€"The need for robust control of technical variables. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 258-272.	3.3	16
32	Connectivity Mapping for Candidate Therapeutics Identification Using Next Generation Sequencing RNA-Seq Data. PLoS ONE, 2013, 8, e66902.	1.1	16
33	PICan: An integromics framework for dynamic cancer biomarker discovery. Molecular Oncology, 2015, 9, 1234-1240.	2.1	15
34	Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer. Oncotarget, 2016, 7, 36632-36644.	0.8	15
35	An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution. Cell Death and Differentiation, 2022, 29, 806-817.	5.0	15
36	The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers. Oncotarget, 2015, 6, 12763-12773.	0.8	14

#	Article	IF	Citations
37	Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data. Clinical Cancer Research, 2022, 28, 4056-4069.	3.2	14
38	In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. Clinical Cancer Research, 2021, 27, 288-300.	3.2	13
39	Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer. Molecular Cancer Therapeutics, 2021, 20, 1627-1639.	1.9	13
40	FLINO: a new method for immunofluorescence bioimage normalization. Bioinformatics, 2022, 38, 520-526.	1.8	12
41	Fibroblast-derived Gremlin1 localises to epithelial cells at the base of the intestinal crypt. Oncotarget, 2019, 10, 4630-4639.	0.8	12
42	Punctate <scp>MLH</scp>1 mismatch repair immunostaining in colorectal cancer. Histopathology, 2019, 74, 795-797.	1.6	11
43	Development of a semiâ€automated method for tumour budding assessment in colorectal cancer and comparison with manual methods. Histopathology, 2022, 80, 485-500.	1.6	11
44	Embracing an integromic approach to tissue biomarker research in cancer: Perspectives and lessons learned. Briefings in Bioinformatics, 2017, 18, bbw044.	3.2	9
45	Downregulation of PPARÎ± during Experimental Left Ventricular Hypertrophy is Critically Dependent on Nox2 NADPH Oxidase Signalling. International Journal of Molecular Sciences, 2020, 21, 4406.	1.8	9
46	KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies. Oncotarget, 2017, 8, 3206-3225.	0.8	9
47	Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer. Oncotarget, 2018, 9, 13834-13847.	0.8	9
48	Pharmacogenomic Profiling and Pathway Analyses Identify MAPK-Dependent Migration as an Acute Response to SN38 in p53 Null and p53-Mutant Colorectal Cancer Cells. Molecular Cancer Therapeutics, 2012, 11, 1724-1734.	1.9	7
49	ACE: A Workbench Using Evolutionary Genetic Algorithms for Analyzing Association in TCGA. Cancer Research, 2019, 79, 2072-2075.	0.4	6
50	IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer. Cell Death Discovery, 2017, 3, 17050.	2.0	5
51	Comment on â€œIdentification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genesâ€. British Journal of Cancer, 2021, 124, 1175-1176.	2.9	5
52	Molecular Subtyping Resource: a user-friendly tool for rapid biological discovery from transcriptional data. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	4
53	Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer. Gut, 2022, 71, 2502-2517.	6.1	4
54	Impact of Variable RNA-Sequencing Depth on Gene Expression Signatures and Target Compound Robustness: Case Study Examining Brain Tumor (Glioma) Disease Progression. JCO Precision Oncology, 2018, 2, 1-17.	1.5	3

#	Article	IF	Citations
55	Intratumoural Epigenetic Heterogeneity in Early Invasive Colorectal Cancer: AÂPrognostic Imprint?. Gastroenterology, 2017, 152, 1622-1623.	0.6	2
56	Response to Park et al. reply to â€˜Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage <scp>II</scp>/<scp>III</scp> colon cancer in a large populationâ€based studyâ€™. Histopathology, 2017, 71, 327-329.	1.6	1
57	Prognosis following surgical resection versus local excision of stage pT1 colorectal cancer: A population-based cohort study. Journal of the Royal College of Surgeons of Edinburgh, 2020, 18, 65-74.	0.8	1